Alendronate Functionalized Bone-Targeting Pomolic Acid Liposomes Restore Bone Homeostasis for Osteoporosis Treatment
In this study, a novel therapeutic agent was designed and constructed to treat osteoporosis, consisting of a liposome material as the drug pocket, PA as the anti-osteoporosis drug, and ALN as the bone-targeting molecule. And our study is the first to employ a bone-targeted delivery system to deliver PA for OVX-induced bone loss, providing an innovative solution for treating osteoporosis.
Authors
- Qingqing Qian (ORCID: https://orcid.org/0000-0003-2578-1360)
- Xiao Dong (ORCID: https://orcid.org/0000-0001-6897-6999)
- Demeng Xia (ORCID: https://orcid.org/0000-0002-1476-2052)
- Ying Liu (ORCID: https://orcid.org/0000-0002-5889-4268)
- Sheng Wang (ORCID: https://orcid.org/0009-0006-8839-3006)
Institutions
- Shanghai University (CN)
- Tongji University (CN)
- Fudan University (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Seventh People's Hospital of Shanghai (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2024-08-01
- DOI
- https://doi.org/10.2147/ijn.s462514
- Citations
- 11
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.57
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality